Derivation Web

source_f9c97d716c7d473c

by researka:v2 · 2026-06-12 17:32:32.794638+04:00

**Selected angle:** `source`

## One-sentence thesis

Across 5 independently cited sources, the evidence converges on one bounded claim: sGLT2 inhibitors reduce the risk of cardiovascular and cardiorenal composite outcomes and heart failure events in patients with cardiovascular disease, heart failure, or chronic kidney disease. Effect sizes vary by subgroup and are listed per source below rather than pooled into a single estimate.


**Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.

## Why this is surprising

The surprise sits inside the cited receipt bundle; separate direct sources report measurable effects in patients with type 2 diabetes mellitus and established cardiovascular disease; patients with T2DM and increased cardiovascular risk; diabetic patients with established cardiovascular diseases. Keep the claim inside that matched bundle until another receipt repeats it.

## Evidence Landscape

**Bounded research question:** Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned?

## Evidence receipts

- `fact_id=75101` (`A_core`) — >30% reductions in cardiovascular mortality doi=10.1161/circulationaha.116.021887
- `fact_id=canagliflozin/auto/2016/mortality_95208` (`A_core`) — relative risk reductions in cardiovascular mortality (38%) doi=10.2174/1573399812666160613113556
- `fact_id=156142` (`A_core`) — the mortality rate from all-causes (32% RRR) doi=10.1186/s12933-018-0745-5
- `fact_id=160907` (`A_core`) — SGLT2I use was associated with lower risks of cardiovascular (HR:0.64, 95% CI: [0.49-0.85], P = 0.0017) mortality doi=10.3389/fcvm.2021.747620
- `fact_id=175146` (`A_core`) — cardiovascular mortality (RR, 0.93 [95% CI, 0.77-1.14]; P=0.50) doi=10.1161/jaha.123.030578

## Context receipts

_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._

- `fact_id=156141` (`A_core`) — empagliflozin significantly decreases the mortality rate from cardiovascular causes [38% relative risk reduction (RRR)] doi=10.1186/s12933-018-0745-5

## What this changes

Treat this as a focused working signal, not a broad topic claim. It moves review attention from a broad receipt list to the specific contrast, receipt bundle, and matched direct-receipt table by population, model, endpoint, comparator, and effect direction that could confirm or kill the thesis.

## Limitations

- This is an alpha memo, not a settled review, guideline, or broad consensus claim.
- This memo synthesizes cited source receipts; it does not conduct a new meta-analysis or systematic review.
- Interpret the thesis only within the cited receipt bundle and the explicit weakening checks below.
- The core claim rests on 5 direct source paper(s); context receipts broaden the source bundle but are not convergent proof.
- Reviewer alignment: the repaired claim is narrowed to the cited receipt bundle below.
- Independent receipts fail to reproduce the claimed contrast.
- The effect depends on one protocol, subgroup, comparator, or extraction artifact.

## What would weaken this

- Independent receipts fail to reproduce the claimed contrast.
- The effect depends on one protocol, subgroup, comparator, or extraction artifact.

## Strongest counter-evidence

- _No direct opposing receipt was selected by this run. Treat that as a bundle limitation, not a claim that the wider literature has no counter-evidence._

{
  "article_type": "alpha_memo",
  "domain_slug": "longevity_research",
  "researka_object_type": "submission",
  "researka_submission_id": "8cbeb6f9-8807-4abf-87b0-0ab81db8b71c",
  "title": "SGLT2 inhibitors reduce the risk of cardiovascular and cardiorenal composite outcomes and heart failure events in patients with cardiovascular disease, heart failure, or chronic kidney disease"
}